Authors
Latest:
A urologist on why the time is right to let go"It is the right time and I have been fortunate to have such great people to work with locally and nationally," a urologist writes.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Male sexual health and reproductive medicine: All that glitters is not gold"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.
Latest:
Study shows QoL sustained with mitomycin gel in low-grade NMIBCThe investigators concluded that a phase 3 trial is warranted.
Latest:
Conservative management feasible for uncomplicated renal colic patients with positive urine cultures“Though septic stones are well recognized as a medical emergency, patients with uncomplicated renal colic (without systemic inflammatory responses or renal impairment) and positive urine cultures pose a dilemma in management considerations,” the investigators explained in their abstract.
Latest:
Case review: An incidentally discovered renal massAn expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
Latest:
Investigators report on real-world recurrence, survival rates in RCC“Our study provides real-world recurrence and survival rates, [however], a major limitation is the retrospective nature of the analysis,” wrote the investigators, led by Viktor Gruenwald, MD, PhD.
Latest:
Dr. Goudelocke outlines stand-up urgency in patients with OAB"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.
Latest:
Olaparib plus abiraterone/prednisone linked with improved PFS in mCRPCThe median PFS was 39 months (95% CI, 22-not reached [NR]) in arm 3 compared with 8.4 months (95% CI, 2.9-17.0) in arm 1 and 14 months (95% CI, 8.4-20.0) in arm 2.
Latest:
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patientsA recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Latest:
AHN Cancer Institute, Illumina to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient CareStudy will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient’s cancer, which may influence choice of treatment based on cancer stage and type.
Latest:
Key Challenges in the Administration of Leuprolide for Advanced/Metastatic Prostate CancerIn the second article of the series, Paul Sieber, MD, shares best practices for the administration of leuprolide in patients with advanced/metastatic prostate cancer.
Latest:
The urologist in the world of precision medicine"What exactly is precision medicine?...One of the original [LUGPA] board members put it very simply: cheaper, faster, and better," writes Raoul S. Concepcion, MD, FACS.
Latest:
The status and future direction of advanced urine testing: multiplex PCR"Given that PCR testing may have a benefit for specific cohorts, it is recommended that more clinical evidence be provided to better guide Medicare in defining 'medical necessity,' ” write Stephanie Gleicher, MD, MPH, and Roger R. Dmochowski MD, MMHC, FACS.
Latest:
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OABExperts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Latest:
Dr. Cheryl Iglesia highlights the evolving treatment paradigm for overactive bladder“New data indicate that long-term use of some of these overactive bladder drugs is not good for cognitive function,” explains Iglesia.
Latest:
Olaparib plus abiraterone confers rPFS, OS benefits in metastatic CRPCClinical benefit with olaparib plus abiraterone was observed in patients with BRCA2, ATM, and CDK12 mutations, which were the most prevalent single-gene HRR mutations across all patients treated.
Latest:
Darolutamide safety in nmCRPC sustained with prolonged exposureSafety findings from the final analysis of the phase 3 ARAMIS trial showed that the androgen receptor inhibitor remained well tolerated with longer treatment.
Latest:
Study assesses impact of health literacy on chronic pelvic painAddressing the gaps in health literacy may lead to improvement in health outcomes and health care disparities among patients with chronic pelvic pain.
Latest:
Automated medical coding benefits both the practice and the patientsWhen you add automation, your medical coding not only improves your margins but also plays a key role in improving patient care.
Latest:
Multidisciplinary Care for Patients With mCRPCIn the third article of this series, Paul E. Dato, MD, provides comprehensive insights on the multidisciplinary care of patients with metastatic castration-resistant prostate cancer.
Latest:
What the SWIU Census reveals about the state of women in urology"As the number of women urologists continues to increase, the field of urology must pay attention to their needs and professional satisfaction as they will constitute an increasing proportion of the future urologic work force," writes Lourdes Guerrios Rivera, MD, MSc.
Latest:
Urologic research and COVID-19: Unmasking the silver liningIn this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.
Latest:
Treatment at high-volume facilities linked to improved survival in node-positive prostate cancerThe improved survival was observed in patients treated at high-volume radiation centers with external-beam radiation therapy plus androgen-deprivation therapy.
Latest:
“Shooting for the Moon” means reducing metastatic prostate cancer diagnoses“We have an incredible opportunity to save countless more lives with better screening practices and renewed recommendations, which accurately reflect the realities we as independent physicians see within our patient populations every day,” Jonathan Henderson, MD, writes in this letter to the editor.
Latest:
Clinical Pearls and Future of Bladder Cancer TreatmentEric A. Singer, MD, MA, FACS, looks to the future of bladder cancer treatment and offers advice for community urologists and urologic oncologists treating patients with the disease.
Latest:
Urologic implications of Lynch syndromeResearch indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.
Latest:
Considerations for palliative care in urologic oncologyBenefits include improved quality of life and symptom management.
Latest:
United Urology Group and its affiliate practices and Prostate Centers USA® are collaborating to revolutionize men's health care with minimally invasive solutionsThe inclusion of PAE in the American Urological Association BPH Guidelines offers a non-surgical alternative that can provide long-term relief with minimal downtime and fewer complications, according to the United Urology Group.
Latest:
Triplet therapy including darolutamide should be standard of care in mCSPC, data indicateResults of the ARASENS trial (NCT02799602) demonstrated that darolutamide plus ADT and docetaxel prolonged overall survival regardless of disease volume or risk.
